
|Articles|February 1, 2010
Daily Dose
Discover this promising alternative for long-term pain management.
Advertisement
Untitled Document
“These formulations show promise as extended-release preparations of opioids, providing therapeutic drug concentrations for up to seven days after a single subcutaneous injection.”
Advertisement
-Lesley J. Smith, DVM, DACVA
From
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
Advertisement
Advertisement
Advertisement
Trending on dvm360
1
FDA conditionally approves combination parasiticide for New World screwworm
2
USDA grants full approval for novel canine parvovirus therapy
3
Generic drug for canine osteoarthritis receives FDA approval
4
Virbac acquires feline hyperthyroidism drug Felanorm in €100 million deal
5




